Dr Reddys Laboratories Ltd vs Themis Medicare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1273 as of 12 Jun 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 7.2 on March 2021 to 45.3 on March 2025 . This represents a CAGR of 44.46% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 257.55 crore on March 2021 to ₹ 1349 crore on March 2025 . This represents a CAGR of 39.28% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 8026 crore as compare to the Dec '25 revenue of ₹ 9024 crore. This represent the decline of -11.06% The revenue of Themis Medicare Ltd for the Mar '26 is ₹ 87.13 crore as compare to the Dec '25 revenue of ₹ 96.93 crore. This represent the decline of -10.11% The ebitda of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 862.5 crore as compare to the Dec '25 ebitda of ₹ 2158 crore. This represent the decline of -60.04% The ebitda of Themis Medicare Ltd for the Mar '26 is ₹ 14.36 crore as compare to the Dec '25 ebitda of ₹ 15.73 crore. This represent the decline of -8.71% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 221.3 crore over 8 quarters. This represents a CAGR of -60.13% The net profit of Themis Medicare Ltd changed from ₹ 24.68 crore to ₹ 8.89 crore over 8 quarters. This represents a CAGR of -39.98% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 14.84 % on March 2021 to 19.23 % on March 2025 . This represents a CAGR of 5.32% over 5 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Themis Medicare Ltd

Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
The Company is principally engaged in the business of manufacturing of finished formulations and synthetic Active Pharmaceutical Ingredients. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Themis Medicare Ltd?

Market cap of Dr Reddys Laboratories Ltd is 106,328 Cr while Market cap of Themis Medicare Ltd is 960 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Themis Medicare Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Themis Medicare Ltd?

As of June 14, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1273.9. On the other hand, Themis Medicare Ltd stock price is INR ₹104.25.

How do dividend payouts of Dr Reddys Laboratories Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.